ChemicalBook > CAS DataBase List > Dideoxyinosine

Dideoxyinosine

Product Name
Dideoxyinosine
CAS No.
69655-05-6
Chemical Name
Dideoxyinosine
Synonyms
DIDANOSINE;DDI;VIDEX;ddino;DDLNO;Dinosin;bmy40900;Videx EC;nsc612049;Didansine
CBNumber
CB0680765
Molecular Formula
C10H12N4O3
Formula Weight
236.23
MOL File
69655-05-6.mol
More
Less

Dideoxyinosine Property

Melting point:
193-195 °C
Boiling point:
193-195 C
alpha 
D25 -26.3° (c = 10 in water)
Density 
1.2917 (rough estimate)
refractive index 
-28 ° (C=0.34, H2O)
storage temp. 
Inert atmosphere,Store in freezer, under -20°C
solubility 
Soluble in DMSO or methanol
form 
Powder
pka
9.12(at 25℃)
color 
White to Off-white
Water Solubility 
1-5 g/100 mL at 21 ºC
Merck 
14,3098
BRN 
3619529
BCS Class
3
Stability:
Stable. Combustible. Incompatible with strong oxidizing agents.
CAS DataBase Reference
69655-05-6(CAS DataBase Reference)
IARC
3 (Vol. 76) 2000
EPA Substance Registry System
Inosine, 2',3'-dideoxy- (69655-05-6)
More
Less

Safety

Hazard Codes 
C
Risk Statements 
34-36/37
Safety Statements 
26-27-36/37/39-45-24/25
WGK Germany 
2
RTECS 
NM7460700
HS Code 
29335990
Hazardous Substances Data
69655-05-6(Hazardous Substances Data)
More
Less

Hazard and Precautionary Statements (GHS)

Symbol(GHS)
Signal word
Warning
Hazard statements

H341Suspected of causing genetic defects

H373May cause damage to organs through prolonged or repeated exposure

Precautionary statements

P201Obtain special instructions before use.

P202Do not handle until all safety precautions have been read and understood.

P260Do not breathe dust/fume/gas/mist/vapours/spray.

P280Wear protective gloves/protective clothing/eye protection/face protection.

P308+P313IF exposed or concerned: Get medical advice/attention.

P405Store locked up.

P501Dispose of contents/container to..…

More
Less

N-Bromosuccinimide Price

Sigma-Aldrich
Product number
D0162
Product name
2′,3′-Dideoxyinosine
Purity
≥98% (HPLC)
Packaging
5mg
Price
$232
Updated
2024/03/01
Sigma-Aldrich
Product number
1191204
Product name
Didanosine
Purity
United States Pharmacopeia (USP) Reference Standard
Packaging
200mg
Price
$1290
Updated
2024/03/01
TCI Chemical
Product number
D3066
Product name
2',3'-Dideoxyinosine
Purity
>98.0%(HPLC)(T)
Packaging
100mg
Price
$33
Updated
2024/03/01
TCI Chemical
Product number
D3066
Product name
2',3'-Dideoxyinosine
Purity
>98.0%(HPLC)(T)
Packaging
500mg
Price
$132
Updated
2024/03/01
Alfa Aesar
Product number
J64833
Product name
2',3'-Dideoxyinosine, 98%
Packaging
250mg
Price
$67.65
Updated
2024/03/01
More
Less

Dideoxyinosine Chemical Properties,Usage,Production

Description

Didanosine is an orally active purine dideoxynucleoside analog indicated for adult and pediatric patients with advanced HIV infection who are either intolerant or significantly deteriorated on zidovudine. It appears to increase CD4 cell counts and decrease p24 antigen levels.Major adverse effects are pancreatitis, peripheral neuropathy and diarrhea.Unlike zidovudine, didanosine exhibits insignificant bone marrow suppression.

Chemical Properties

White Powder

Originator

National Cancer Institute(NIH) (U.S.A.)

Uses

Used as an antiviral

Uses

Antiviral;Transrcriptase inverse inhibitor

Uses

2?,3?-Dideoxyinosine is a potent anti-retroviral agent. It is most effective in combination therapy for the treatment of HIV and related lymphoma.

Definition

ChEBI: A purine 2',3'-dideoxyribonucleoside that is inosine in which the hydroxy groups at both the 2' and the 3' positions on the sugar moiety have been replaced by hydrogen.

Indications

Didanosine (ddI, Videx) is an adenosine analogue with activity against HIV-1, HIV-2, and HTLV-I. It is approved as part of a multidrug regimen for the therapy of HIV infection and is also used as postexposure HIV prophylaxis

Manufacturing Process

In a 500 ml flask with a shoulder was separately charged 50 ml of medium (pH 7.0) containing 0.5 g/dl of yeast extract, 1.0 g/dl of peptone, 1.0 g/dl of meat extract and 0.5 g/dl of NaCl followed by sterilization. One platinum loop of each microorganism shown in Table which had been preincubated in bouillon agar medium at 30°C for 16 hours was inoculated on the medium followed by shake culture at 30°C for 16 hours. After the cells were isolated from the obtained culture solution by centrifugal separation, the cells were washed with 0.05 M Tris-HCl buffer (pH 7.2) and further centrifuged to give washed cells.
The washed cells described above were added to 0.05 M Tris-HCl buffer (pH 7.2) containing 1 g/dl of 2',3'-dideoxyadenosine in a concentration of 5 g/dl followed by reacting at 30°C for 2 hours. The amount of 2',3'-dideoxyinosine produced at this stage is shown in the next Table.
This way 2',3'-dideoxyinosine may be produced from 2',3'-dideoxyadenosine in a short period of time, by contacting microorganisms supplied at low cost, products containing the same or treated products thereof, with a substrate.

brand name

Videx (Bristol-Myers Squibb).

Therapeutic Function

Antiviral

Antimicrobial activity

Didanosine is active against HIV-1, HIV-2 and HTLV-1.

Acquired resistance

Codon changes at positions 65 or 74 in HIV reverse transcriptase are associated with reduced susceptibility.

General Description

Fluffy white solid or powder. Condenses at 347°F and darkens at approximately 572°F. Odorless.

General Description

Didanosine (Videx, ddI) is 2',3'-dideoxyinosine (ddI), a synthetic purine nucleoside analog that is bioactivatedto 2',3'-dideoxy-ATP (ddATP) by host cellularenzymes.The metabolite, ddATP, accumulates intracellularly,where it inhibits RT and is incorporated intoviral DNA to cause chain termination in HIVinfectedcells. The potency of didanosine is 10-to 100-foldless than that of AZT with respect to antiviral activity andcytotoxicity, but the drug causes less myelosuppressionthan AZT causes.
Didanosine is recommended for the treatment of patientswith advanced HIV infection who have received prolongedtreatment with AZT but have become intolerant to, or experiencedimmunosuppression from, the drug. AZT and ddIact synergistically to inhibit HIV replication in vitro, andddI is effective against some AZT-resistant strains of HIV.Painful peripheral neuropathy (tingling, numbness, and painin the hands and feet) and pancreatitis (nausea, abdominalpain, elevated amylase) are the major dose-limiting toxicitiesof didanosine. Didanosine is given orally in the form ofbuffered chewable tablets or as a solution prepared from thepowder. Both oral dosage forms are buffered to preventacidic decomposition of ddI to hypoxanthine in the stomach.

Air & Water Reactions

Water soluble.

Health Hazard

SYMPTOMS: Symptoms of exposure to a related compound include cutaneous eruptions, fever, mouth sores, thrombocytopenia, neutropenia, reversible peripheral neuropathy, gastrointestinal distress, headache, nausea and vomiting.

Fire Hazard

Flash point data for Dideoxyinosine are not available; however, Dideoxyinosine is probably combustible.

Pharmaceutical Applications

An analog of deoxyadenosine, formulated for oral administration.

Mechanism of action

Didanosine (ddl) is a purine dideoxynucleoside, which is an analogue of inosine. Chemically, it is 2′,3′-dideoxyinosine, and it differs from inosine by having hydrogen atoms in place of the 2′- and 3′-hydroxyl groups on the ribose ring. Didanosine is a pro-drug that is bioactivated by metabolism to dideoxyadenosine triphosphate, which is a competitive inhibitor of viral RT and is incorporated into the developing viral DNA in place of deoxyladenosine triphosphate. As such, this agent causes chain termination because of the absence of a 3′-hydroxyl group. Didanosine inhibits HIV RT and exerts a virustatic effect on the retroviruses. Combined with ZDV, antiretroviral activity of ddI is increased.

Pharmacokinetics

Oral absorption: c. 40%
Cmax 400 mg once daily: 0.93 mg/L
Plasma half-life: c. 1.4 h
Volume of distribution: c. 1 L/kg
Plasma protein binding: <5%
Absorption
Bioavailability is reduced by about half when taken with food and the drug should be given at least 30 min before a meal. The peak plasma concentration achieved by enteric-coated tablets is less than half that of buffered tablets.
Distribution
Central nervous system (CNS) penetration is relatively poor. Median concentrations in semen (455 ng/mL; range < 50–2190 ng/mL) are greater than those in blood (<50 ng/mL; range <50–860 ng/mL). It is secreted in breast milk.
Metabolism
Based upon animal studies it is presumed that metabolism occurs by the pathways responsible for the elimination of endogenous purines by xanthine oxidase. Metabolism may be altered in patients with severe hepatic impairment; however, no specific dose adjustment is recommended.
Excretion
Renal clearance by glomerular filtration and active tubular secretion accounts for 50% of total body clearance. Urinary recovery accounts for about 20% of the oral dose in adults. The half-life increases three-fold in patients requiring dialysis. Patients with a creatinine clearance <60 mL/min may be at greater risk of toxicity.

Clinical Use

Treatment of HIV infection (in combination with other antiretroviral drugs)

Clinical Use

The most common adverse effect produced by didanosine is diarrhea.Abdominal pain, nausea, vomiting, anorexia, and dose-related peripheral neuropathy may occur. Pancreatitis occurs rarely, as do hyperuricemia, bone marrow suppression, retinal depigmentation, and optical neuritis. Resistance to didanosine appears to result from mutations different from those responsible for zidovudine resistance.

Side effects

Most serious are pancreatitis (fatal and non-fatal), lactic acidosis and severe hepatomegaly with steatosis (fatal and nonfatal), retinopathy, optic neuritis and dose-related peripheral neuropathy. Patients with low body weight may require dose modification. A strong association with non-cirrhotic portal hypertension has been described.
The combination with stavudine should be avoided in pregnant women as fatal cases of lactic acidosis have been reported. Caution should also be exercised in patients with known risk factors for liver disease. Therapy should be stopped in patients who develop clinical or laboratory evidence of lactic acidosis or hepatotoxicity. Monitoring lactate levels prospectively is not recommended as mild hyperlactatemia occurs in asymptomatic patients and has a poor positive predictive value for the development of lactic acidosis.
Caution should be exercised in co-administering other drugs with known neurotoxicity and in patients with a history of neuropathy. Treatment should stop if symptoms and signs of neuropathy are observed, but the condition is usually reversible and patients with resolved neuropathy may be retreated at a reduced dosage. Retinal depigmentation has been observed in children and twice-yearly dilated retinal examination is recommended.

Drug interactions

Potentially hazardous interactions with other drugs
Allopurinol: concentration of didanosine increased - avoid.
Antibacterials: ciprofloxacin, tetracyclines, and other antibiotics affected by indigestion remedies - do not administer within 2 hours of didanosine.
Antivirals: absorption of atazanavir reduced (give at least 2 hours before or 1 hour after didanosine tablets); manufacturer of darunavir advises to take didanosine 1 hour before or 2 hours after darunavir; didanosine tablets reduce absorption of indinavir (give at least 1 hour apart); concentration possibly increased by ganciclovir, valganciclovir and tenofovir - avoid with tenofovir; give didanosine and ritonavir at least 2.5 hours apart; increased risk of side effects with ribavirin and stavudine - avoid; concentration reduced by tipranavir (give tipranavir and didanosine capsules at least 2 hours apart); give didanosine 2 hours before or 4 hours after rilpivirine.
Cytotoxics: increased risk of toxicity with hydroxycarbamide - avoid.
Orlistat: absorption of didanosine possibly reduced.

Metabolism

Didanosine is less toxic than ZDV. The CSF fluid/plasma ratio of ddI is 0.2. Didanosine is ultimately converted to hypoxanthine, xanthine, and uric acid through the usual metabolic pathway for purines. The latter is a nontoxic metabolic product.
Didanosine is given in advanced HIV infection, ZDV intolerance, or significant clinical/immunologic deterioration.

Precautions

Buffering agents that are compounded with didanosineto counteract its degradation by gastric acid mayinterfere with the absorption of other drugs that requireacidity (e.g., indinavir, delavirdine, ketoconazole, fluoroquinolones,tetracyclines, dapsone). An enteric-coatedformulation (Videx EC) that dissolves in the basic pH ofthe small intestine is not susceptible to these interactions.Ganciclovir and valganciclovir can increase bloodlevels of didanosine.The use of zalcitabine with didanosineis not recommended because that combination carriesan additive risk of peripheral neuropathy.The combinationof didanosine with stavudine increases the riskof pancreatitis, hepatotoxicity, and peripheral neuropa-thy. Stavudine should not be given with didanosine topregnant women because of the increased risk of metabolicacidosis.

Dideoxyinosine Preparation Products And Raw materials

Raw materials

2,2'-Azobis(2-methylpropionitrile) Chloroform Carbon disulfide Tributyltin Hydride Tetrahydrofuran Inosine 3-BROMOPROPIONITRILE Tetrachlorosilane Tetrabutylammonium fluoride

Preparation Products

More
Less

Dideoxyinosine Suppliers

Americas 1 Canada 1 China 252 Europe 3 Finland 1 France 1 Germany 5 India 19 Japan 2 Slovakia 1 Switzerland 1 United Kingdom 12 United States 53 Global 352
LGM Pharma
Tel
1-(800)-881-8210
Fax
615-250-9817
Email
inquiries@lgmpharma.com
Country
United States
ProdList
2123
Advantage
70
AdooQ BioScience, LLC
Tel
+1 (866) 930-6790
Fax
+1 (866) 333-9607
Email
info@adooq.com
Country
United States
ProdList
2782
Advantage
58
HBCChem, Inc.
Tel
+1-510-219-6317
Fax
+1-650-486-1361
Email
sales@hbcchem.com
Country
United States
ProdList
10648
Advantage
60
Target molecule Corp.
Tel
857-239-0968
Fax
857-239-8801
Email
service1@targetmol.com
Country
United States
ProdList
2559
Advantage
60
TargetMol Chemicals Inc.
Tel
+1-781-999-5354 +1-00000000000
Email
marketing@targetmol.com
Country
United States
ProdList
32159
Advantage
58
InvivoChem
Tel
+1-708-310-1919 +1-13798911105
Fax
708-557-7486
Email
sales@invivochem.cn
Country
United States
ProdList
6391
Advantage
58
BOC Sciences
Tel
+1-631-485-4226
Fax
1-631-614-7828
Email
inquiry@bocsci.com
Country
United States
ProdList
19552
Advantage
58
Alchem Pharmtech,Inc.
Tel
8485655694
Email
sales@alchempharmtech.com
Country
United States
ProdList
63687
Advantage
58
Protheragen-ING
Tel
+16313385890
Email
info@protheragen-ing.com
Country
United States
ProdList
3868
Advantage
58
Aladdin Scientific
Tel
Email
tp@aladdinsci.com
Country
United States
ProdList
57505
Advantage
58
ApexBio Technology
Tel
--
Fax
--
Email
sales@apexbt.com
Country
United States
ProdList
6251
Advantage
58
Focus Synthesis LLC
Tel
--
Fax
--
Email
acd@focussynthesis.com
Country
United States
ProdList
2487
Advantage
61
Sisco Research Laboratories Pvt. Ltd.
Tel
--
Fax
--
Email
srlmarketing@dishnetdsl.net
Country
United States
ProdList
1905
Advantage
64
Cayman Chemical Company
Tel
--
Fax
--
Email
cayman@caymanchem.com
Country
United States
ProdList
6213
Advantage
81
MedChemExpress
Tel
--
Fax
--
Email
sales@medchemexpress.com
Country
United States
ProdList
6398
Advantage
58
MYLAN LABORATORIES LTD
Tel
--
Fax
--
Email
info@amstock.com
Country
United States
ProdList
179
Advantage
58
Combi-Blocks Inc.
Tel
--
Fax
--
Email
sales@combi-blocks.com
Country
United States
ProdList
6618
Advantage
69
Medical Isotopes, Inc
Tel
--
Fax
--
Email
info@medicalisotopes.com
Country
United States
ProdList
3180
Advantage
58
Riedel-de Haen AG
Tel
--
Fax
--
Country
United States
ProdList
6773
Advantage
87
TCI America
Tel
--
Fax
--
Email
sales@tciamerica.com
Country
United States
ProdList
6909
Advantage
75
Frontier Scientific, Inc.
Tel
--
Fax
--
Email
sales@frontiersci.com
Country
United States
ProdList
6222
Advantage
86
Matrix Scientific
Tel
--
Fax
--
Email
sales@matrixscientific.com
Country
United States
ProdList
6632
Advantage
80
3B Scientific Corporation
Tel
--
Fax
--
Email
sales@3bsc.com
Country
United States
ProdList
6962
Advantage
56
Berry & Associates, Inc.
Tel
--
Fax
--
Email
orders@berryassoc.com
Country
United States
ProdList
535
Advantage
66
Fragmenta
Tel
--
Fax
--
Email
sales@fragmenta.com
Country
United States
ProdList
1068
Advantage
0
AlliChem, LLC
Tel
--
Fax
--
Email
sales@allichemllc.com
Country
United States
ProdList
6516
Advantage
60
Ryan Scientific, Inc.
Tel
--
Fax
--
Email
ryan.reichlyn@ryansci.com
Country
United States
ProdList
6439
Advantage
60
Chem-Impex International, Inc.
Tel
--
Fax
--
Country
United States
ProdList
6730
Advantage
64
Waterstone Technology, LLC
Tel
--
Fax
--
Email
sales@waterstonetech.com
Country
United States
ProdList
6786
Advantage
30
Altan Corporation
Tel
--
Fax
--
Email
OrderingService@AltanBiochemicals.com
Country
United States
ProdList
1161
Advantage
30
2A PharmaChem USA
Tel
--
Fax
--
Email
sales@2apharmachem.com
Country
United States
ProdList
6137
Advantage
39
ACIC Fine Chemicals Inc.
Tel
--
Fax
--
Email
sales@acic.com
Country
United States
ProdList
492
Advantage
48
3B Scientific Corporation
Tel
--
Fax
--
Email
sales@3bsc.com
Country
United States
ProdList
6718
Advantage
47
United States Biological
Tel
--
Fax
--
Email
chemicals@usbio.net
Country
United States
ProdList
6214
Advantage
80
HONEST JOY HOLDINGS LIMITED
Tel
--
Fax
--
Email
sales@honestjoy.cn
Country
United States
ProdList
6675
Advantage
54
AK Scientific, Inc.
Tel
--
Fax
--
Email
sales@aksci.com
Country
United States
ProdList
6347
Advantage
65
APAC Pharmaceutical, LLC
Tel
--
Fax
--
Email
sales@apacpharma.com
Country
United States
ProdList
6322
Advantage
38
Wilshire Chemical Company Inc.
Tel
--
Fax
--
Email
WilshrChem@AOL.COM
Country
United States
ProdList
3498
Advantage
58
TimTec Corporation
Tel
--
Fax
--
Country
United States
ProdList
1945
Advantage
58
Advanced Molecular Technologies
Tel
--
Fax
--
Email
enquiries@amtechpl.com
Country
United States
ProdList
136
Advantage
38
NetQem
Tel
--
Fax
--
Email
sales@netqem.us
Country
United States
ProdList
1641
Advantage
38
Lab Express
Tel
--
Fax
--
Email
sales@labexpress.com
Country
United States
ProdList
1577
Advantage
67
BOSCHE SCIENTIFIC, LLC
Tel
--
Fax
--
Email
Sales@BoscheSci.com
Country
United States
ProdList
6477
Advantage
55
American Custom Chemicals Corporation
Tel
--
Fax
--
Email
sales@acccorporation.com
Country
United States
ProdList
6820
Advantage
51
CGeneTech, Inc.
Tel
--
Fax
--
Email
qyu@cgenetech.com
Country
United States
ProdList
959
Advantage
30
TriLink BioTechnologies, Inc.
Tel
--
Fax
--
Email
support@trilinkbiotech.com
Country
United States
ProdList
262
Advantage
69
Beta Pharma, Inc.
Tel
--
Fax
--
Email
sales@betapharma.com
Country
United States
ProdList
6226
Advantage
60
Chontech, Inc.
Tel
--
Fax
--
Email
chontech@yahoo.com
Country
United States
ProdList
1101
Advantage
30
LKT Laboratories, Inc.
Tel
--
Fax
--
Email
info@lktlabs.com
Country
United States
ProdList
2164
Advantage
64
Spectrum Chemicals & Laboratory Products
Tel
--
Fax
--
Email
sales@spectrumchemical.com
Country
United States
ProdList
6699
Advantage
77
More
Less

View Lastest Price from Dideoxyinosine manufacturers

Hebei Mujin Biotechnology Co.,Ltd
Product
Dideoxyinosine 69655-05-6
Price
US $0.00/KG
Min. Order
1KG
Purity
99%
Supply Ability
50000KG/month
Release date
2023-09-05
Hebei Chuanghai Biotechnology Co., Ltd
Product
Dideoxyinosine 69655-05-6
Price
US $10.00/KG
Min. Order
1KG
Purity
99%
Supply Ability
10 mt
Release date
2024-11-04
Dideu Industries Group Limited
Product
Dideoxyinosine 69655-05-6
Price
US $1.10/g
Min. Order
1g
Purity
99.9%
Supply Ability
100 Tons Min
Release date
2021-07-15

69655-05-6, DideoxyinosineRelated Search:

5'-O-Dimethoxytrityl-N-isobutyryl-deoxyguanosine 3'-GMP DISODIUM SALT Guanosine GUANOSINE 3':5'-CYCLIC MONOPHOSPHATE SODIUM SALT 2'-Deoxyinosine Disodium 5'-Inosinate 2'-Deoxyguanosine-5'-diphosphate trisodium salt 2',3'-O-Isopropylideneinosine N2-Isobutyryl-2'-deoxyguanosine 2',3',5'-TRI-O-ACETYLINOSINE 3'-AMINO-2',3'-DIDEOXYINOSINE 2',3'-DIDEHYDRO-2',3'-DIDEOXYINOSINE Inosine N2-ISOBUTYRYL-3'-O-BENZOYL-2'-DEOXYGUANOSINE 5'-O-(4,4'-DIMETHOXYTRITYL)-N2-ISOBUTYRYL-2'-DEOXYGUANOSINE-3'-(METHYL-N,N-DIISOPROPYL)PHOSPHORAMIDITE INOSINE-3',5'-CYCLIC PHOSPHATE N2,2'-O-DIBUTYRYLGUANOSINE 3':5'-CYCLIC MONOPHOSPHATE SODIUM SALT 8-BR-CGMP

  • bmy40900
  • ddino
  • nsc612049
  • 2',3'-Dideoxy inosine(DDI)
  • DDI, Didanosine
  • 2.3-Dideoxy
  • 2',3'-Dideoxy-D-inosine
  • DIDANOSINE / 2'',3''-DIDEOXYINOSINE
  • DdI (nucleoside)
  • Inosine, 2',3'-dideoxy-
  • dideoxyinosine(didanosine)
  • 9-(2,3-Dideoxy-beta-D-ribofuranosyl)-6-oxopurine
  • 9-(2,3-Dideoxy-beta-D-ribofuranosyl)hypoxanthine
  • Didansine
  • VIDEX
  • 2',3'-DIDEOXYINDOSINE
  • 2',3'-DIDEOXYINOSINE
  • DIDANOSINE
  • dideoxyinosine
  • DDLNO
  • DDI
  • 2’,3’-dideoxy-inosin
  • 2’,3’-didoxyinosine
  • 2',3'-DIDEOXYINOSINE extapure
  • NSC-612049：Videx
  • ddI, ddIno
  • 9-[(2R,5S)-5-(Hydroxymethyl)oxolan-2-yl]-3H-purin-6-one
  • Didanosine SysteM Suitability Mixture
  • ddI 9-(2,3-Dideoxy-beta-D-ribofuranosyl)-6-oxopurine Didanosine 9-(2,3-Dideoxy-beta-D-ribofuranosyl)hypoxanthine
  • 2, 3-DIDEOXY INOSINE SODIUM SALT
  • 9-((2R,5S)-5-(hydroxyMethyl)tetrahydrofuran-2-yl)-9H-purin-6-ol
  • Didanosine (200 mg)
  • 2',3'-ddI
  • 2',3'-Dideoxyinosine, 98%, reverse transcriptase inhibitor
  • 9-[(2R,5S)-5-(hydroxymethyl)oxolan-2-yl]-6,9-dihydro-1H-purin-6-one
  • 2';3'-DIDEOXYINOSINE;VIDEX EC;DDI;VIDEX
  • 3'-Dideoxyinosine
  • Videx EC
  • DIDANOSINE(VIDEX)
  • Didanosine for system suitability CRS
  • Didanosine CRS
  • 2',3'-Dideoxyinosine&gt
  • 9-((2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl)-1H-purin-6(9H)-one
  • 2’,3’-dideoxyinosine, DDI, didanosine
  • Dideoxyinosine USP/EP/BP
  • DidanosineQ: What is Didanosine Q: What is the CAS Number of Didanosine Q: What is the storage condition of Didanosine Q: What are the applications of Didanosine
  • 2,3-Dideoxyinosine (ddI, ddIno) extrapure, 98%
  • Didanosine (1191204)
  • Didanosine System Suitability Mixture (1191215)
  • Dinosin
  • 2', 3'-Dideoxyinosine
  • Didanosine, 10 mM in DMSO
  • DIDANOSINE USP
  • 69655-05-6
  • 69655-05-5
  • Nucleosides, Nucleotides, Oligonucleotides
  • Nucleoside Analogs
  • Immune Cell Signaling and Blood